Shanghai Pharma Biotherapeutics USA

What Shanghai Pharma Biotherapeutics USA does

Shanghai Pharma Biotherapeutics USA Inc. (SPHBio) is a privately-held, wholly-owned US subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH), one of the largest pharmaceutical groups in China. Headquartered in San Diego with 101-250 employees, SPHBio is structured as a cross-border biotherapeutics bridge entity. Its stated mission is to identify and acquire Chinese rights to novel therapeutics from international innovators — serving as the liaison to initiate clinical testing and registration in China through SPH's infrastructure — while simultaneously developing novel SPH-originated therapeutics in the US and identifying US-based partners for them, alongside conducting its own R&D in dedicated research laboratories.

The company's core operations span biotherapeutic research, development, and clinical trials, with therapeutic-area focus in CNS, Digestive & Metabolic, Immune System, Oncology, and Cerebral & Cerebrovascular conditions. Its product surface is anchored by parent SPH's portfolio of over 700 pharmaceutical products (646 in China's National Reimbursement Drug List) and 50 cGMP-certified manufacturing facilities, giving SPHBio access to vertically-integrated infrastructure covering R&D, manufacturing, distribution, and retail. Distribution reach through SPH extends to over 30,000 medical institutions and over 2,000 retail pharmacies in China, with $200M deployed annually by the parent into R&D.

The business model is enterprise partnership-driven rather than direct commercial. SPHBio functions as a B2B intermediary, generating value through licensing of Chinese market rights, US development partnerships for SPH assets, and co-development with academic and industry collaborators. End customers of the broader SPH ecosystem include Chinese hospitals and retail pharmacy consumers; SPHBio's direct customers are researchers, collaborators, and investors. The company does not publicly disclose standalone revenue, pricing, or product pricing models, and operates as a cost center supported by parent SPH's $23B (2018) operating revenue base.

Name

Shanghai Pharma Biotherapeutics USA

Legal name

Shanghai Pharma Biotherapeutics USA Inc.

Website

https://sphbio.com

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

SPHBio is the US-based, wholly-owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH), focused on biotherapeutic R&D, clinical trials, and cross-border licensing between US innovators and SPH's China pharmaceutical infrastructure.

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

Keywords

• Biopharmaceutical research
• Antibody drug conjugates
• Clinical development services
• Pharmaceutical licensing
• Drug registration services

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling pharmaceutical products including prescription drugs, with 646 products included in the National Reimbursement Drug List.

Go-to-market motion1 record

Distribution channels2 records

Core offering

SPHBio operates as a biotherapeutic research and development subsidiary that identifies and acquires Chinese rights to novel therapeutics, initiates clinical testing and regulatory registration in China, and develops novel therapeutics originating from parent SPH in the US market. The company conducts cutting-edge R&D in its laboratories, specializing in antibody drug conjugates (ADCs), and partners with international biopharmaceutical innovators, researchers, and investors to advance therapeutics addressing unmet medical needs.

Product overview

SPHBio operates as a biopharmaceutical company offering a broad portfolio of over 700 pharmaceutical products and novel therapeutics. The company functions as a bridge for bringing Chinese-developed therapeutics to the US market while also advancing US-developed innovations in China. Their portfolio covers multiple therapeutic areas including CNS, Digestive & Metabolic, Immune System, Oncology, and Cerebral & Cerebrovascular diseases, supported by cGMP-certified manufacturing capabilities through parent company SPH.

Differentiator

Problem solved

Functional benefit

Products and services

• Chinese Rights Acquisition and Licensing for Novel Therapeutics Identification, evaluation, and acquisition of Chinese market rights for novel therapeutics developed by international biopharmaceutical innovators. SPHBio serves as the liaison between partners and parent SPH to initiate clinical testing and regulatory registration in China. Targeted at international biopharmaceutical innovators and partners.
• US-Based Novel Therapeutic Development Development of novel SPH-originating therapeutics in the United States, including identification of potential commercial partners. Targeted at biopharmaceutical partners, collaborators, and investors.
• Clinical Testing and Regulatory Registration Services in China Initiation and management of clinical testing and registration of novel therapeutics in China through SPH's regulatory and clinical infrastructure. Targeted at biopharmaceutical innovators seeking China market entry.
• Biotherapeutic R&D Laboratory Services Cutting-edge research and laboratory-based identification of novel therapeutics, with focus on antibody drug conjugates (ADCs) and therapeutic areas including CNS, Digestive & Metabolic, Immune System, Oncology, and Cerebral & Cerebrovascular conditions. Targeted at researchers, collaborators, and investors.

Quantifiable outcome

• 50 cGMP-certified manufacturing facilities
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Shanghai Pharmaceuticals Holding Co., Ltd. (SPH)flagshipOthersSPHBio is a wholly-owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH), one of the largest pharmaceutical companies in China. SPH is a vertically-integrated and diversified pharmaceutical group with dual listings on Shanghai (601607) and Hong Kong (02067) stock exchanges.

Scale indicators8 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• BeiGene: Beijing-headquartered biopharmaceutical company with substantial US operations developing oncology therapeutics including biologics. Closely comparable cross-border US-China biopharma business model with global clinical development capabilities.
• HUTCHMED (China) Limited: Hong Kong-listed Chinese biopharma with US clinical operations focused on oncology and immunology therapeutics. Operates a similar model of developing innovative therapeutics in China while expanding into global markets, with comparable regulatory and commercial infrastructure.
• Innovent Biologics: Chinese biopharmaceutical company developing innovative biologics including oncology antibodies and ADCs. Comparable in biologics manufacturing capabilities, China-US dual market strategy, and therapeutic area focus.

Broad incumbents

• Pfizer: Global pharmaceutical company with major ADC capabilities following the Seagen acquisition. Comparable in oncology biologics focus and represents both potential partnership/licensing target and competitive pressure in the ADC space.
• Daiichi Sankyo: Japanese pharmaceutical company and global ADC leader (Enhertu with AstraZeneca). Comparable in ADC therapeutic modality focus and oncology pipeline depth; represents the gold-standard benchmark SPHBio's ADC programs would need to compete against.
• AstraZeneca: Global pharmaceutical company with leading ADC franchise through Enhertu partnership with Daiichi Sankyo. Comparable in oncology biologics development and global clinical/commercial capabilities, representing both a potential partner and competitive threat.
• Gilead Sciences: Global biopharmaceutical company with major ADC franchise (Trodelvy) following Immunomedics acquisition. Comparable in oncology ADC commercialization capabilities and represents both competitive pressure and potential out-licensing partner.

Emerging players

• I-Mab Biopharma: Chinese-US biopharmaceutical company developing innovative immuno-oncology therapeutics with US clinical operations. Comparable cross-border business model focused on biologics for oncology indications.
• Junshi Biosciences: Chinese biopharma with US clinical operations developing innovative therapeutics including immuno-oncology and ADCs. Comparable cross-border development model with focus on biologics innovation originating from China.

Others

• WuXi Biologics: Hong Kong-listed Chinese biologics CDMO providing development and manufacturing services globally. Comparable in biologics manufacturing scale and China-based operations supporting global biopharma innovation, though operates as a service provider rather than developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shanghai-pharma-biotherapeutics-usa-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Pharma Biotherapeutics USA